Last updated on March 2020

A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation

Brief description of study

This study will investigate if nivolumab will improve recurrence-free survival (RFS) compared to placebo in participants with HCC who have undergone complete resection or have achieved a complete response after local ablation, and who are at high risk of recurrence

Clinical Study Identifier: NCT03383458

Find a site near you

Start Over

Local Institution

Kurume-shi, Japan
  Connect »